XmAb657
Multispecific antibody
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT07284797 NCT07284797 · Idiopathic Inflammatory Myopathies Registry: NCT07284797 | 1 | Percentage of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) (Through Week 52) 2028-10 | In progress: results expected 1 Oct 2028 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1 (1)
What this study did
Competitive landscape
Other CD19 x CD3 drugs
Blinatumomab, Surovatamig, CLN-978. Compare all 4 CD19 x CD3 drugs
3 other tracked programmes target this mechanism, 2 of them ahead of this one.
This drug's own stage for Idiopathic Inflammatory Myopathies: Phase 1. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| XmAb657: this drug | Phase 1 | Multispecific antibody | CD19 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Blinatumomab | Approved(overall) | Multispecific antibody | CD19 x CD3 | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Brepocitinib (Lisraya) | Approved | Small molecule | TYK2/JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| Repository Corticotropin (Acthar Gel) | Approved | Peptide | Melanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Anifrolumab | Phase 3 | Monoclonal antibody | Type I interferon receptor subunit 1 (IFNAR1) | not yet graded | No reviewed efficacy summary in this indication | |
| Surovatamig | Phase 3(overall) | Multispecific antibody | CD19 x CD3 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| CLN-978 | Phase 1(overall) | Multispecific antibody | CD19 x CD3 | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow XmAb657 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.